(2S,3R,4S,5R,6R)-2-[(3S,4R,5R,6S)-2,5-Dihydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:151963

Synonyms

beta-D-galacto-hexopyranosyl-(1->2)-[beta-D-galacto-hexopyranosyl-(1->3)]-6-deoxy-L-galacto-hexopyranose
Gal(b1-2)[Gal(b1-3)]Fuc
WURCS=2.0/2,3,2/[a1221m-1x_1-5][a2112h-1b_1-5]/1-2-2/a2-b1_a3-c1

Definition

References

GlyGen:G50616AZ
GlyTouCan:G50616AZ

Ontology

ChEBI ( EBI )

Relationships

is a type of: glycoside

glycoside Show first 5 Terms

Phenotype

Phenotype resulting from (2S,3R,4S,5R,6R)-2-[(3S,4R,5R,6S)-2,5-Dihydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5R,6R)-2-[(3S,4R,5R,6S)-2,5-Dihydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5R,6R)-2-[(3S,4R,5R,6S)-2,5-Dihydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model